Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Dušan Andoljšek"'
Publikováno v:
Zdravniški Vestnik, Vol 81, Iss SUPL II (2012)
Background: Advances in the treatment of haemophilia patients have led to a significant increase in life expectancy. Diseases and conditions developing now were not previously encountered in this population group as patients were dying younger. Preva
Externí odkaz:
https://doaj.org/article/be93758611fc4cf5a9d6ba8053215ab1
Autor:
Dušan Andoljšek, Irena Preložnik Zupan
Publikováno v:
Zdravniški Vestnik, Vol 81, Iss SUPL II (2012)
Background: We retrospectively analysed major surgical procedures and complications for a period of 11 years and tried to find out if the reasons for surgery were population specific or the same as in general population. Methods: Retrospective analys
Externí odkaz:
https://doaj.org/article/1cca547b9ef04edfa47bc0eb947a4e6f
Autor:
Dušan Andoljšek, Tadej Pajič
Publikováno v:
Zdravniški Vestnik, Vol 77, Iss SUPPI (2008)
BACKGROUND The principle of treatment or prevention of bleeding in von Willebrand disease (vWd)is correction of dual plasma deficiency of von Willebrand factor (vWF) and factor VIII(F VIII). This can be achieved by desmopressin (DDAVP) or plasma frac
Externí odkaz:
https://doaj.org/article/ed42263a340c43a3881d3ee90f3ef489
Autor:
Dušan Andoljšek, Samo Zver
Publikováno v:
Zdravniški Vestnik, Vol 73, Iss 0 (2004)
Background. Recombinant factor VIIa can induce hemostasis and controls bleeding in surgery in hemophilia inhibitor patients and in other hemostatic disorders, e.g. thrombocytopenia, platelet function disorders, coagulation disorders due to drugs and
Externí odkaz:
https://doaj.org/article/a23506ba389641e2949fe8a5de7f61a4
Autor:
Samo Zver, Dušan Andoljšek
Publikováno v:
Zdravniški Vestnik, Vol 73, Iss 0 (2004)
Background. Recombinant factor VIIa (rFVIIa), which is currently registered only for the treatment of haemophilia A and B patients with inhibitors, is seen increasingly as a possible universal haemostatic agent in untractable bleedings. One possible
Externí odkaz:
https://doaj.org/article/069f74985bc34f5e888628146cfc688c
Autor:
Dušan Andoljšek
Publikováno v:
Zdravniški Vestnik, Vol 73, Iss 0 (2004)
Externí odkaz:
https://doaj.org/article/9bd2052a1352436b82a928d5e0387995
Autor:
Dušan Andoljšek
Publikováno v:
Obzornik zdravstvene nege, Vol 32, Iss 3/4 (1998)
Externí odkaz:
https://doaj.org/article/b0d49d68a9824a2d88c3773a40d364e0
Autor:
Dušan Andoljšek
Publikováno v:
Obzornik zdravstvene nege, Vol 25, Iss 3/4 (1991)
Externí odkaz:
https://doaj.org/article/fe7fcef0592645298f11e89f07db92eb
Autor:
Mario Poljak, A. Lekše, Jeffrey V. Lazarus, I. Preložnik Zupan, Majda Benedik Dolničar, B. Faganel, M. Kozinc, Mojca Maticic, Dušan Andoljšek
Publikováno v:
Journal of Hepatology. 68:S193-S194
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bfd4ebf84f262c04330afb0178fe7afe
https://doi.org/10.1016/s0168-8278(18)30599-3
https://doi.org/10.1016/s0168-8278(18)30599-3
Autor:
Andreas Hillarp, Saša Anžej Doma, Peter Černelč, Dušan Andoljšek, Irena Preldžnik Zupan, Tadej Pajič
Publikováno v:
Biochemia Medica
Volume 26
Issue 2
Volume 26
Issue 2
Acquired inhibitors to coagulation factors other than factor VIII are extremely rare. We describe a case of a 59-year-old woman with abnormal bleeding, diagnosed with concurrent inhibitor antibodies to factor VIII and IX by Bethesda testing. We demon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5644213a8c62cef6e68a2cddfbb6f58e
https://hrcak.srce.hr/161711
https://hrcak.srce.hr/161711